CompletedPhase 2NCT00407459

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

Studying Pleural mesothelioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Armando Santoro, MD
Principal Investigator
Armando Santoro, MD
Istituto Clinico Humanitas
Intervention
Bevacizumab, Pemetrexed, Carboplatin(drug)
Enrollment
77 target
Eligibility
18 years · All sexes
Timeline
20072010

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00407459 on ClinicalTrials.gov

Other trials for Pleural mesothelioma

Additional recruiting or active studies for the same condition.

See all trials for Pleural mesothelioma

← Back to all trials